Department of Health Sciences, University of Milan, 20142 Milan, Italy.
Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.
Int J Mol Sci. 2021 Mar 15;22(6):2980. doi: 10.3390/ijms22062980.
In the last few decades, the newly emerging field of epigenetic regulation of glycosylation acquired more importance because it is unraveling physiological and pathological mechanisms related to glycan functions. Glycosylation is a complex process in which proteins and lipids are modified by the attachment of monosaccharides. The main actors in this kind of modification are the glycoenzymes, which are translated from glycosylation-related genes (or glycogenes). The expression of glycogenes is regulated by transcription factors and epigenetic mechanisms (mainly DNA methylation, histone acetylation and noncoding RNAs). This review focuses only on these last ones, in relation to cancer and other diseases, such as inflammatory bowel disease and IgA1 nephropathy. In fact, it is clear that a deeper knowledge in the fine-tuning of glycogenes is essential for acquiring new insights in the glycan field, especially if this could be useful for finding novel and personalized therapeutics.
在过去的几十年中,新兴的糖基化表观遗传调控领域因其揭示了与聚糖功能相关的生理和病理机制而变得更加重要。糖基化是一个复杂的过程,在此过程中,蛋白质和脂质通过单糖的附着而被修饰。这种修饰的主要参与者是糖基化酶,它由与糖基化相关的基因(或糖基因)翻译而来。糖基因的表达受转录因子和表观遗传机制(主要是 DNA 甲基化、组蛋白乙酰化和非编码 RNA)的调节。这篇综述仅关注与癌症和其他疾病(如炎症性肠病和 IgA1 肾病)相关的最后一种机制。事实上,深入了解糖基因的精细调控对于在聚糖领域获得新的见解是至关重要的,特别是如果这对发现新的、个性化的治疗方法有帮助的话。